RPR-115135, a farnesyltransferase inhibitor, increases 5-FU- cytotoxicity in ten human colon cancer cell lines: role of p53. (Q44062538)

29 November 2017

RPR-115135, a farnesyltransferase inhibitor, increases 5-FU- cytotoxicity in ten human colon cancer cell lines: role of p53. (English)

1 reference

29 November 2017

0 references

1 reference

Patrizia Russo

1

1 reference

29 November 2017

Davide Malacarne

2

1 reference

29 November 2017

Carla Falugi

3

1 reference

29 November 2017

Sonya Trombino

4

1 reference

29 November 2017

Patrick M O'Connor

5

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

International Journal of Cancer

29 November 2017

10

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

29 November 2017

100

1 reference

29 November 2017

3

1 reference

29 November 2017

266-275

1 reference

Molecular predictors of survival after adjuvant chemotherapy for colon cancer

29 November 2017

1 reference

Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation

21 January 2018

1 reference

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

21 January 2018

1 reference

New directions in the treatment of colorectal cancer: a look to the future

21 January 2018

1 reference

Signal transduction from multiple Ras effectors

21 January 2018

1 reference

Blocking oncogenic Ras signaling for cancer therapy

21 January 2018

1 reference

Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic

21 January 2018

1 reference

Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues

21 January 2018

1 reference

Farnesyltransferase inhibitors: potential role in the treatment of cancer

21 January 2018

1 reference

Current status of clinical trials of farnesyltransferase inhibitors.

21 January 2018

1 reference

Multivariate data analysis using D-optimal designs, partial least squares, and response surface modeling: A directional approach for the analysis of farnesyltransferase inhibitors

21 January 2018

1 reference

Nonpeptidomimetic farnesyltransferase inhibitor RPR-115135 increases cytotoxicity of 5-fluorouracil: role of p53.

21 January 2018

1 reference

Correlations of partial and extensive methylation at the p14(ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors

21 January 2018

1 reference

Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia

21 January 2018

1 reference

INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53.

21 January 2018

1 reference

21 January 2018

p53: only ARF the story

1 reference

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

21 January 2018

1 reference

Manumycin and gliotoxin derivative KT7595 block Ras farnesylation and cell growth but do not disturb lamin farnesylation and localization in human tumour cells

21 January 2018

1 reference

Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade

21 January 2018

1 reference

Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.10461

1 reference

29 November 2017

1 reference